Arcturus Therapeutics Holdings (ARCT) Current Leases (2019 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 8 years of Current Leases data on file, last reported at $4.3 million in Q1 2026.

• Quarterly Current Leases rose 17.32% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 17.32% YoY) and the FY2025 annual result came in at $4.2 million, up 18.64% from the prior year.
• Current Leases climbed to $4.3 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $4.3 million in Q4 2023 to a low of $1.7 million in Q1 2022.
• A 5-year average of $3.8 million and a median of $4.0 million in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases jumped 155.09% — and 2024, when it dropped 18.21%.
• Tracing ARCT's Current Leases over 5 years: stood at $3.9 million in 2022, then grew by 10.94% to $4.3 million in 2023, then fell by 17.57% to $3.6 million in 2024, then grew by 18.64% to $4.2 million in 2025, then climbed by 2.21% to $4.3 million in 2026.
• The last three Current Leases figures came in at $4.3 million (Q1 2026), $4.2 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.